Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: Analyses of the ARIES observational cohort study

Pharmacoepidemiology and Drug Safety

Volumn 23, Issue 7, 2014, Pages 726-734

  Grothey, Axel ^a   Flick, E Dawn ^b   Cohn, Allen L ^c   Bekaii Saab, Tanios S ^d   Bendell, Johanna C ^e   Kozloff, Mark ^f   Roach, Nancy ^g   Mun, Yong ^b   Fish, Susan ^b   Hurwitz, Herbert I ^h  

^a MAYO CLINIC   (United States)

^b GENENTECH INC   (United States)

^c Rocky Mountain Cancer Center   (United States)

^d THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^e SARAH CANNON RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

^g Patient Advocacy   (United States)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bevacizumab; Colorectal cancer; Cumulative exposure; Observational study; Pharmacoepidemiology; Treatment beyond progression; Treatment patterns

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER REGISTRY; CANCER SURGERY; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; COLORECTAL SURGERY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; FEMALE; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; OBSERVATIONAL STUDY; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SUDDEN CARDIAC DEATH; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; VERY ELDERLY; YOUNG ADULT; ADOLESCENT; COLORECTAL NEOPLASMS; DISEASE COURSE; FOLLOW UP; METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SURVIVAL RATE; TIME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; COHORT STUDIES; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE; TIME FACTORS; YOUNG ADULT;

EID: 84903816000     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3633     Document Type: Article

References (16)

1. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342. doi:10.1056/NEJMoa032691.
2. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005; 23: 3706-3712. doi:10.1200/JCO.2005.00.232.
3. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-1544. doi:10.1200/JCO.2006.09.6305.
4. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-65. doi:10.1200/JCO.2003.10.066.
5. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005; 23: 3697-3705. doi:10.1200/JCO.2005.05.112.
6. Bennouna J, Sastre J, Arnold D, et al. ML18147 Study Investigators. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013; 14: 29-37. doi:10.1016/S1470-2045(12)70477-1.
7. Kozloff M, Yood MU, Berlin J, et al. Investigators of the BRiTE study (2009) Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist 14: 862-870.
8. Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008; 26: 5326-5334. doi:10.1200/JCO.2008.16.3212.
9. Lash TL, Cole SR. Immortal person-time in studies of cancer outcomes. J Clin Oncol 2009; 27: e55-e56. doi:10.1200/JCO.2009.24.1877.
10. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 2008; 167: 492-499. doi:10.1093/aje/kwm324.
11. Shintani AK, Girard TD, Eden SK, Arbogast PG, Moons KG, Ely EW. Immortal time bias in critical care research: application of time-varying Cox regression for observational cohort studies. Crit Care Med 2009; 37: 2939-2945. doi:10.1097/CCM.0b013e3181b7fbbb.
12. Zietemann VD, Schuster T, Duell TH. Post-study therapy as a source of confounding in survival analysis of first-line studies in patients with advanced non-small-cell lung cancer. J Thorac Dis 2011; 3: 88-98. doi:10.3978/j.issn.2072-1439.2010.12.07.
13. Flick ED, Barr C, Dalal D, Mun Y, Purdie D, Dong W. Estimation of treatment effect beyond disease progression in a metastatic cancer population: examples from two observational cohort studies. Pharmacoepidemiology Drug Saf 2011; 20(Suppl s1): 746. doi:10.1002/pds.2206.
14. Flick ED, Barr CE, Fish S, Leon L, Mun Y, Dalal D. Dose-response relationship between post-progression bevacizumab exposure and survival among metastatic colorectal cancer patients. Pharmacoepidemiology Drug Saf 2012; 21(Suppl s3): 244. doi:10.1002/pds.3324.
15. Genentech, Inc. Avastin prescribing information. 2013.
16. Bennouna J, Borg C, Delord JP, et al. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study. Clin Colorectal Cancer 2012; 11: 38-44. doi:10.1016/j.clcc.2011.05.002.